Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. More information is available at www.armatapharma.com
Location: United States, California, Marina del Rey
Employees: 51-200
Total raised: $50M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Bioscience... | bioscience... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.01.2023 | - | $30M | - |
| 27.01.2021 | - | $20M | - |